GLP-1 for Adults 60+: SELECT Trial Benefits and Muscle Loss Risk

Obesity in older adults carries the same health risks as in younger adults

The first thing to understand is this: obesity does not become less of a health concern when you turn 60. Cardiovascular disease, type 2 diabetes, joint pain, reduced mobility, and metabolic dysfunction are just as clinically significant at 65 as they are at 45. In fact, for older adults, the functional impact of excess weight on independence and quality of life can be even more pronounced.

If you are over 60 and have been struggling with your weight, you may have been told that dieting at your age is harder. That is true. But the problem is not age itself. The problem is that the traditional calorie-deficit approach does not account for how your body’s hormonal and metabolic systems have changed. That is where GLP-1 medications can make a real difference.

The SELECT trial: specific evidence for adults over 60

The most relevant clinical trial for older adults considering GLP-1 treatment is the SELECT trial, published in 2023 and 2024 in the New England Journal of Medicine^[1]. This trial specifically enrolled adults with cardiovascular disease or cardiovascular risk, a mean age of approximately 61.6 years, and obesity or overweight status.

The trial randomized 17,604 participants across 41 countries to receive either semaglutide 2.4 mg weekly or placebo. The primary outcome was major adverse cardiovascular events: non-fatal heart attack, non-fatal stroke, or cardiovascular death.

Over 5 years, semaglutide reduced the risk of major adverse cardiovascular events by 20% compared to placebo^[1]. That is approximately one cardiovascular event prevented for every 67 people treated for 5 years. For older adults with existing cardiovascular disease or significant cardiovascular risk, this evidence is directly applicable.

The trial also reported weight loss outcomes. Participants on semaglutide lost an average of approximately 9-10% of body weight compared to 2-3% in the placebo group. This was sustained over 5 years of treatment.

Older adults respond to GLP-1 medication as effectively as younger adults

One question you may have is whether GLP-1 medications work as well for weight loss at 60 or 70 as they do at 40. The clinical data says yes.

Subgroup analyses from the STEP 1 trial (examining semaglutide)^[2] and SURMOUNT-1 trial (examining tirzepatide)^[3] both examined weight loss outcomes across age groups. Older adults (60 and above) achieved comparable weight loss to younger participants. The medication’s mechanism of action, reducing appetite through GLP-1 receptor activation in the brain, does not substantially diminish with age.

It is true that older adults may lose weight slightly more slowly on average due to a lower baseline metabolic rate. But the medication is effective. The difference is not clinically meaningful in most cases.

The core age-specific concern: sarcopenia and muscle loss

The key distinction for older adults on GLP-1 medications is not about safety or efficacy of weight loss. It is about what kind of weight you lose and at what rate.

Sarcopenia, or age-related muscle loss, is already a concern in adults 60 and older^[4]. Starting at age 30, most people begin to lose approximately 0.5% of muscle mass per year, accelerating after 60. This is a natural part of aging. By the time you reach 70, you may have lost 30-40% of the muscle mass you had at 30.

Muscle loss in older adults has real consequences. It is associated with increased fall risk, bone fractures, reduced independence, and worse overall health outcomes. It is not just a cosmetic concern.

When you lose weight rapidly, you lose both fat and lean mass (muscle, bone, and other tissues). The proportion varies, but SURMOUNT-1 data suggests that approximately 25-30% of weight lost on GLP-1 medications is lean mass rather than fat^[3].

For a 45-year-old losing 40 pounds on GLP-1, that means 30-40 pounds of fat loss and 10-12 pounds of lean mass loss. That is manageable. For a 68-year-old losing the same 40 pounds, the same 10-12 pounds of lean mass loss is more clinically significant because of lower baseline muscle reserve and reduced capacity to rebuild.

This is not a reason to avoid GLP-1 treatment. It is a reason to structure your treatment specifically to minimize muscle loss through resistance training and adequate protein intake.

Protein intake and resistance training: non-negotiable for older adults on GLP-1

If you are 60 or older and starting GLP-1 medication, your nutrition and exercise approach needs to be intentional about muscle preservation.

Protein targets: Aim for 1.2-1.6 grams of protein per kilogram of body weight daily. For a 170-pound (77 kg) person, that is 92-123 grams of protein per day. For a 200-pound (91 kg) person, that is 109-146 grams. This is higher than the general population recommendation because you are fighting against age-related muscle loss and the muscle-loss risk from substantial weight loss.

When appetite is suppressed by GLP-1, hitting these protein targets requires intention. Prioritize protein-rich foods at each meal. Consider protein shakes or supplements if you are not hitting targets through food alone.

Resistance training: Do resistance training 2-3 times per week. This includes weight training, resistance bands, bodyweight exercises (squats, push-ups), or any structured approach that creates muscle tension and stimulates strength adaptation. Aim for at least 8-10 repetitions of exercises targeting major muscle groups.

Resistance training is not optional. It is what signals your body to preserve muscle during weight loss. Without it, your body preferentially sheds muscle because muscle tissue is metabolically expensive to maintain.

Bone density and substantial weight loss in older adults

Bone density naturally declines with age, particularly for women after menopause. Substantial weight loss is associated with modest reductions in bone mineral density, both from the weight loss itself and potentially from the medication’s effects.

For younger adults, this is usually not clinically significant. For adults 60 and older, particularly those with existing osteoporosis or osteopenia risk, it warrants attention.

What to do: Ensure adequate calcium intake (1,000-1,200 mg daily depending on age), adequate vitamin D (800-1,000 IU daily minimum, likely higher for some), and weight-bearing and resistance exercise, which both improve bone density.

Your provider may recommend a baseline DXA scan (bone density scan) before starting treatment if you have risk factors for bone density loss, and follow-up monitoring during treatment. This is not required for all patients but is appropriate for those with significant osteoporosis risk or prior fractures.

Gastrointestinal side effects in older adults

The most common side effects of GLP-1 medications are gastrointestinal: nausea, constipation, diarrhea, and reduced appetite. Most patients adapt within a few weeks, but in older adults, these side effects warrant particular attention.

Dehydration risk: Older adults have a reduced thirst sensation and lower total body water. Vomiting or diarrhea from GLP-1 side effects carries a higher dehydration risk in older patients. Dehydration can have serious consequences, including acute kidney injury, falls, and confusion.

Slower dose escalation: Your provider may recommend starting at a lower dose and escalating more slowly than the standard protocol. A slower schedule gives your gastrointestinal system more time to adapt and reduces the risk of significant nausea or other side effects.

Monitoring: Stay hydrated. Drink water consistently throughout the day, not just when you feel thirsty. If you experience persistent vomiting or diarrhea, contact your provider. These side effects usually resolve, but if they do not, dose adjustment is appropriate.

Polypharmacy: GLP-1 and multiple medications

Most older adults take multiple medications for blood pressure, cholesterol, heart rhythm, or other conditions. GLP-1 medications slow gastric emptying, which can affect how other oral medications are absorbed.

Some oral medications require consistent absorption for their effect. Blood thinners, blood pressure medications, hormone therapies, and diabetes medications may have altered absorption if taken with GLP-1 medications.

This does not mean you cannot take GLP-1 if you are on other medications. It means you need clear communication with your provider about your complete medication list. Your provider will:

• Review the timing of your other medications
• Check whether any require special spacing or dosing adjustments with GLP-1
• Monitor your clinical response more closely
• Adjust doses if needed

This is routine clinical work, not a barrier to treatment. But it is essential that you disclose all medications and supplements to your provider before starting.

Menopause and perimenopause context for women 50-65

If you are a woman in your 50s or early 60s, you may overlap with menopause. Estrogen decline during menopause and perimenopause contributes to multiple changes that compound the challenges of weight loss at this life stage.

Estrogen influences where your body stores fat (perimenopause often shifts fat distribution toward the abdomen), how your metabolism works, and how your appetite-regulating hormones function. Estrogen also supports bone density and muscle mass. As estrogen declines, your bone density naturally decreases, and your muscle loss accelerates.

If you are considering GLP-1 treatment during perimenopause or early menopause, the protein intake and resistance training recommendations above are even more important. You are fighting against multiple biological forces at the same time: estrogen decline, age-related muscle loss, and the muscle-loss effect of substantial weight loss.

Some patients on GLP-1 treatment also use hormone therapy. This is a conversation to have with your provider. Hormone therapy does not contraindicate GLP-1 treatment, but the combination should be coordinated.

Who is appropriate for GLP-1 treatment, and who requires extra consideration

Appropriate candidates: Older adults with obesity or overweight status, adequate nutritional status (normal or adequate albumin and protein stores), no medical contraindications, willing to do resistance training, and able to maintain adequate protein intake.

Adults with obesity-related cardiovascular disease, type 2 diabetes, joint pain limiting mobility, or other obesity-related conditions are particularly appropriate candidates. The functional improvement from modest weight loss (10-15 pounds) can meaningfully improve quality of life, mobility, and independence.

Require extra consideration: Older adults with pre-existing sarcopenia or frailty (extremely low muscle mass or strength), severe untreated osteoporosis, advanced chronic kidney disease (GLP-1 medications increase the risk of dehydration, and kidney function affects medication clearance), significant polypharmacy where drug interactions are complex or dangerous, or very limited capacity to do resistance training or maintain adequate nutrition.

These patients may still be candidates for GLP-1 treatment, but they require more careful provider oversight and may benefit from a different approach (slower dose escalation, lower target doses, more frequent monitoring).

The case for GLP-1 in older adults despite the age-specific considerations

Obesity in older adults is not less important than obesity at 40. Cardiovascular disease, mobility impairment, reduced quality of life, and metabolic disease are real problems at any age. They matter more, not less, because they directly affect independence and how long you can maintain the life you want to live.

GLP-1 medications work for weight loss in older adults. The SELECT trial, with a mean participant age of 62, showed dramatic cardiovascular benefit. Smaller trials show that functional improvements from modest weight loss in older adults translate to better mobility, reduced pain, improved strength, and greater independence.

The muscle loss and bone density concerns are real. They are also manageable. Resistance training and adequate protein intake are not exotic interventions. They are evidence-based approaches that older adults are fully capable of doing. Most of your age-specific risk is preventable with proper structure and monitoring.

How Transformation Health evaluates older adults

When you complete an assessment with Transformation Health, your information goes to an independent, licensed provider. That provider reviews your complete health history: your age, any cardiovascular events, current medications, kidney function, bone health if available, and your capacity for exercise and nutrition changes.

If you are 60 or older, the provider will explicitly discuss the age-specific considerations with you:

• The muscle loss risk and the importance of resistance training and protein intake
• The potential for bone density effects and whether baseline monitoring is appropriate
• Your complete medication list and potential interactions
• Your capacity and willingness to do resistance training
• Whether a slower dose escalation schedule is appropriate given your GI tolerance or overall health

If the provider determines that treatment is appropriate, your medication is prepared by a licensed US compounding pharmacy. Your monthly fee covers the medication, ongoing provider care, any required lab work, and access to medical weight loss coaching.

Your coaching team will include guidance on nutrition (hitting protein targets with reduced appetite) and exercise (how to structure resistance training appropriately for your age and fitness level).

Residents of Arkansas, Delaware, Mississippi, New Mexico, Rhode Island, Washington DC, and West Virginia are required by state law to complete a live video consultation before a prescription can be written.

What to know about our medications

Transformation Health works exclusively with US-based, licensed compounding pharmacies. Our semaglutide and tirzepatide are compounded medications, not FDA-approved branded products.

The active ingredients have been studied extensively in clinical trials, including the SELECT trial showing cardiovascular benefit in older adults. The SELECT trial data is from branded semaglutide. Our approach allows licensed prescribers to personalize medications by adding additional ingredients to address adverse side effects or sensitives, in addition to allowing for custom dosing based on a patient’s specific needs. These personalized medications are prepared by licensed compounding pharmacies and it is important to know that compounded medications are not FDA-approved. They have not been independently evaluated by the FDA for safety, efficacy, or quality, and may differ from branded versions in formulation, purity, or potency.

Our pricing is all-inclusive: your monthly fee covers medication, lab work (through Quest or Labcorp), provider consultations, and access to our coaching team. No hidden fees. You can cancel anytime.

Semaglutide starts at $249 per month for the injectable version or $279 for the oral version. Tirzepatide is $339 per month. Your provider will recommend which medication and dose is appropriate based on your health history and goals.

How to get started

Complete a free online assessment. Tell us about your age, your weight, your cardiovascular history, your current medications, your exercise capacity, and your goals. An independent, licensed provider reviews your information and responds within 24 hours to determine whether treatment is medically appropriate for you.

Be specific about your age and any age-related health concerns. This helps the provider evaluate the muscle loss risk, bone health, medication interactions, and whether your situation warrants special considerations.

If treatment is appropriate, your medication ships within days. Your coaching team will reach out to discuss nutrition strategies for hitting protein targets and how to structure resistance training appropriate for your age and fitness level.

Citations

[1] Lincoff AM et al. “Semaglutide and Cardiovascular Outcomes in Obesity Without Previous Myocardial Infarction or Stroke.” New England Journal of Medicine. 2023;389(22):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/

[2] Wilding JPH et al. “Weight Reduction with Semaglutide (STEP) Trial.” New England Journal of Medicine. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/

[3] Jastreboff AM et al. “Tirzepatide for Weight Reduction (SURMOUNT-1) Trial.” New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

[4] Rosenberg IH. “Sarcopenia: Origins and Clinical Relevance.” Journal of Nutrition. 1997;127(5):990S-991S.